Deep Dive: IL Inhibitor and JAK Inhibitor in Atopic Dermatitis

Published Date: 05 Jun 2026

IL-4 and IL-13 drive the inflammation that breaks down the skin barrier and fuels the “atopic march” when atopic dermatitis (AD) progresses to other allergic diseases. Dupilumab blocks signaling through both pathways, delivering disease control that can persist even after treatment discontinuation in some patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Beyond What Is Visible in Myelofibrosis?

2.

MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information

3.

ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology

4.

Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue

5.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot